<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Gavriatopoulou, M.</style></author><author><style face="normal" font="default" size="100%">Kyrtsonis, M.-C.</style></author><author><style face="normal" font="default" size="100%">Michael, M.</style></author><author><style face="normal" font="default" size="100%">Hadjiharissi, E.</style></author><author><style face="normal" font="default" size="100%">Symeonidis, A.</style></author><author><style face="normal" font="default" size="100%">Michalis, E.</style></author><author><style face="normal" font="default" size="100%">Repoussis, P.</style></author><author><style face="normal" font="default" size="100%">Tsatalas, K.</style></author><author><style face="normal" font="default" size="100%">Sioni, A.</style></author><author><style face="normal" font="default" size="100%">Kartasis, Z.</style></author><author><style face="normal" font="default" size="100%">Stefanoudaki, E.</style></author><author><style face="normal" font="default" size="100%">Voulgarelis, M.</style></author><author><style face="normal" font="default" size="100%">Delimpasi, S.</style></author><author><style face="normal" font="default" size="100%">Gika, D.</style></author><author><style face="normal" font="default" size="100%">Vervesou, E.</style></author><author><style face="normal" font="default" size="100%">Konstantopoulos, K.</style></author><author><style face="normal" font="default" size="100%">Kokkini, G.</style></author><author><style face="normal" font="default" size="100%">Zomas, A.</style></author><author><style face="normal" font="default" size="100%">Roussou, P.</style></author><author><style face="normal" font="default" size="100%">Anagnostopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Economopoulos, T.</style></author><author><style face="normal" font="default" size="100%">Terpos, E.</style></author><author><style face="normal" font="default" size="100%">Zervas, K.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prognostication of the high-risk WM patient</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Lymphoma, Myeloma and Leukemia</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953707927&amp;doi=10.3816%2fCLML.2011.n.028&amp;partnerID=40&amp;md5=9fd65f9357a5d3460f98dedb685bb722</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">127 - 129</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Waldenström's macroglobulinemia is characterized by a protracted course in most patients and the median survival may be long. However, a subset of patients may present with more aggressive disease that is associated with short survival. In order to better characterize these &quot;poor-risk&quot; patients, we identified patients who died within 2 years from the initiation of front-line treatment. These patients were older and had more often features of aggressive disease, such as elevated LDH and low serum albumin than the standard-risk population. Furthermore, only a minority of poor-risk patient had a response to initial therapy. However, conventional clinical factors or even the lack on response could not adequately identify poor-risk patients, indicating the need for novel molecular or other markers that would be able to effectively recognize patients at greatest need for aggressive therapies. © 2011 Elsevier Inc. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><notes><style face="normal" font="default" size="100%">Export Date: 21 February 2017</style></notes></record></records></xml>